A Study to Evaluate ERAS-801 in Patients With Recurrent Glioblastoma (THUNDERBBOLT-1)

Inclusion Criteria: * Age ≥ 18 years * Willing and able to give written informed consent * Diagnosis of Glioblastoma, IDH WT as defined by the WHO 2021 criteria * Adequate organ function * Willing to comply with all protocol-required visits, assessments, and procedures * Able to swallow oral medication Exclusion Criteria: * Prior treatment with an EGFR inhibitor for Glioblastoma * Currently enrolled in another therapeutic study * History of clinically significant cardiovascular disease * Gastrointestinal conditions that may affect administration/absorption of oral medications * Have an active infection (bacterial, fungal, or viral) requiring systemic therapy * Pregnant or breastfeeding women * Any serious underlying medical or psychiatric condition or evidence of any other significant clinical disorder or laboratory finding that renders the patient inappropriate to participate in the study * Known allergies, hypersensitivity, or intolerance to ERAS-801 or its excipients